ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 576,80
-0,73%
Dow Jones
40 211,72
0,53%
DAX
18 515,83
-0,45%
Brent Oil
83,54
-0,95%
Bitcoin
63 465,82
-2,14%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Intellia Therapeutics Inc (NTLA)

  7. Intellia Therapeutics Inc (NTLA) Actualités

NTLA

Intellia Therapeutics (NTLA)

Intellia Therapeutics Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:NTLA
DateHeureSourceTitreSymboleSociété
26/06/202117h16PR Newswire (US)Intellia and Regeneron Announce Landmark Clinical Data Showing Deep Reduction in Disease-Causing Protein After Single Infusio...NASDAQ:NTLAIntellia Therapeutics Inc
26/06/202100h15Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:NTLAIntellia Therapeutics Inc
24/06/202123h22Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:NTLAIntellia Therapeutics Inc
24/06/202113h30GlobeNewswire Inc.Intellia Therapeutics Names James Basta, J.D., as Executive Vice President, General Counsel and Corporate SecretaryNASDAQ:NTLAIntellia Therapeutics Inc
22/06/202113h00Business WireBlackstone Life Sciences, Cellex Cell Professionals, and Intellia Therapeutics Launch New CAR T-Cell CompanyNASDAQ:NTLAIntellia Therapeutics Inc
04/06/202113h30GlobeNewswire Inc.Intellia Therapeutics to Present Interim Clinical Data from Ongoing Phase 1 Study of NTLA-2001 for the Treatment of Transthyr...NASDAQ:NTLAIntellia Therapeutics Inc
06/05/202122h08Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:NTLAIntellia Therapeutics Inc
29/04/202113h30GlobeNewswire Inc.Intellia Therapeutics to Hold Conference Call to Discuss First Quarter 2021 Earnings and Company UpdatesNASDAQ:NTLAIntellia Therapeutics Inc
28/04/202122h54Edgar (US Regulatory)Additional Proxy Soliciting Materials (definitive) (defa14a)NASDAQ:NTLAIntellia Therapeutics Inc
28/04/202122h39Edgar (US Regulatory)Proxy Statement (definitive) (def 14a)NASDAQ:NTLAIntellia Therapeutics Inc
27/04/202122h35GlobeNewswire Inc.Intellia Therapeutics Announces Presentations at the 24th American Society of Gene and Cell Therapy Annual MeetingNASDAQ:NTLAIntellia Therapeutics Inc
12/04/202113h30GlobeNewswire Inc.Intellia Therapeutics Names Georgia Keresty, Ph.D., M.P.H., to Board of DirectorsNASDAQ:NTLAIntellia Therapeutics Inc
30/03/202113h30GlobeNewswire Inc.Intellia Therapeutics’ Investigational CRISPR Treatment NTLA-2001 Receives European Union Orphan Drug Designation for ATTR ...NASDAQ:NTLAIntellia Therapeutics Inc
25/03/202112h30GlobeNewswire Inc.Intellia Therapeutics Presents New Data on Expanded Cell Engineering Capabilities Utilizing Base EditorsNASDAQ:NTLAIntellia Therapeutics Inc
10/03/202113h30GlobeNewswire Inc.Intellia Therapeutics Presents Preclinical Proof of Concept for CRISPR-based In Vivo Editing of Bone Marrow at Keystone eSymp...NASDAQ:NTLAIntellia Therapeutics Inc
26/02/202112h31Edgar (US Regulatory)Securities Registration: Employee Benefit Plan (s-8)NASDAQ:NTLAIntellia Therapeutics Inc
25/02/202113h30GlobeNewswire Inc.Intellia Therapeutics Announces Fourth Quarter and Full-Year 2020 Financial ResultsNASDAQ:NTLAIntellia Therapeutics Inc
18/02/202113h30GlobeNewswire Inc.Intellia Therapeutics to Hold Conference Call to Discuss Fourth Quarter and Full-Year 2020 Earnings and Company UpdatesNASDAQ:NTLAIntellia Therapeutics Inc
16/02/202123h08Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:NTLAIntellia Therapeutics Inc
22/01/202123h00Edgar (US Regulatory)Amended Statement of Beneficial Ownership (sc 13d/a)NASDAQ:NTLAIntellia Therapeutics Inc
07/01/202113h30GlobeNewswire Inc.Intellia Therapeutics Highlights Strategic Priorities and Anticipated Development Milestones for 2021NASDAQ:NTLAIntellia Therapeutics Inc
12/12/202015h00GlobeNewswire Inc.Intellia Therapeutics Achieves Normal Human Alpha-1 Antitrypsin Protein Levels in Non-Human Primates Through Targeted Gene In...NASDAQ:NTLAIntellia Therapeutics Inc
05/12/202016h00GlobeNewswire Inc.Intellia Therapeutics Presents New Preclinical Data Supporting Its CRISPR/Cas9-Engineered TCR-T Cell Treatment for Acute Myel...NASDAQ:NTLAIntellia Therapeutics Inc
04/12/202022h01GlobeNewswire Inc.Intellia Therapeutics Announces Closing of $201 Million Public Offering of Common Stock, Including Full Exercise of Underwrit...NASDAQ:NTLAIntellia Therapeutics Inc
02/12/202022h01Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(5) (424b5)NASDAQ:NTLAIntellia Therapeutics Inc
02/12/202003h30GlobeNewswire Inc.Intellia Therapeutics Announces Pricing of Public Offering of Common StockNASDAQ:NTLAIntellia Therapeutics Inc
30/11/202022h03Edgar (US Regulatory)Automatic Shelf Registration Statement of Securities of Well-known Seasoned Issuers (s-3asr)NASDAQ:NTLAIntellia Therapeutics Inc
30/11/202022h01GlobeNewswire Inc.Intellia Therapeutics Announces Proposed Public Offering of Common StockNASDAQ:NTLAIntellia Therapeutics Inc
11/11/202013h30GlobeNewswire Inc.Intellia Therapeutics Receives Grant to Develop Curative CRISPR/Cas9 In Vivo Sickle Cell Disease TreatmentsNASDAQ:NTLAIntellia Therapeutics Inc
09/11/202013h30GlobeNewswire Inc.Intellia Therapeutics Doses First Patient in Landmark CRISPR/Cas9 Clinical Trial of NTLA-2001 for the Treatment of Transthyre...NASDAQ:NTLAIntellia Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:NTLA

Dernières Valeurs Consultées

LSE
XI08
Citi Fun 25
TSXV
MGO
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés